Bone turnover assessment: A good surrogate marker?;Avaliação da remodelação óssea: Um bom marcador substituto?

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 2, 2010, Pages 99-105

  Dreyer, Patrícia ^a   Vieira, José Gilberto H ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biochemical markers; Bone turnover; Fracture; Osteoporosis

Indexed keywords

EID: 77952685258     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000200003     Document Type: Review

References (54)

1. Vieira JG. Considerações sobre os marcadores bioquímicos do metabolismo ósseo e sua utilidade prática. Arq Bras Endocrinol Metab. 1999;43(6):415-22.
2. Committee for medicinal products for medical use. Guideline on the evaluation of medical products in the treatment of primary osteoporosis. European Medicines Agency, London, UK, 2006.
3. Food and Drug Administration. Guidelines for preclinical and clinical evaluation of agents used in the prevention of treatment of postmenopausal osteoporosis. Food and Drug Administration, Washington, DC, USA, 1994.
4. Bouxsein ML, Delmas PD. Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res. 2008;23(8):1155-67.
5. Cummins SR, Bates D, Black DM. Clinical use of bone densitometry: clinical applications. JAMA. 2002;288(15):1898-900.
6. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185-94.
7. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteopos Int. 2004;15(12):1003-8.
8. Burr DB. Introduction - Bone turnover and fracture risk. J Musculoskelet Neuronal Interact. 2003;3(4):408-9.
9. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385-97.
10. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337-49.
11. Burnett-Bowie SM, Saag K, Sebba A, de Papp AE, Chen E, Rosenberg E, et al. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab. 2009;94(4):1097-03.
12. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006;119(4 Suppl 1):S25-31.
13. Martin TJ, Seeman E. Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab. 2008;22(5):701-22.
14. Kushida K, Takahashi M, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab. 1995;80(8):2447-50.
15. Risteli J, Risteli L. Products of bone collagen metabolism. Dynamics of bone and cartilage metabolism. Seibel MJ, Robins SP, Bilezikian JP, editors. San Diego, Academic press; 1999. p. 275-87.
16. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002;30(6):886-90.
17. Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrod B. Clearance of NH2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med. 1994;179(2):405-12.
18. Garnero P, Delmas PD. Assessment of the serum levels of alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab. 1993;77(4):1046-53.
19. Eastell R, Hannon RA. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008;67(2):157-62.
20. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. Measurement of serum osteocalcin with a humanspecific two-site immunoradiometric assay. J Bone Miner Res. 1992;7(12):1389-98.
21. Schlemmer A, Hassager C. Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur J Endocrinol. 1999;140(4):332-7.
22. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem. 1984;53:717-48.
23. Kamel S, Brazier M, Néri V, Picard C, Samson L, Desmet G, et al. Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by chromatographic and immunoassay methods. J Bone Miner Res. 1995;10(9):1385-92.
24. Ivaska KK, Lenora J, Gerdhem P, Akesson K, Väänänen HK, Obrant KJ. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab. 2008;93(7):2622-32.
25. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31(1):57-61.
26. Marcus R. Exercise: moving in the right direction. J Bone Miner Res. 1998;13(12):1793-6.
27. Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, et al. Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab. 2007;92(2):443-9.
28. Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Delmas PD, Eastell R, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and United States. J Bone Miner Res. 2009;24(3):389-97.
29. Uebelhart D, Bernard J, Hartmann DJ, Moro L, Roth M, Uebelhart B, et al. Modifications of bone and connective tissue after orthostatic bedrest. Osteopos Int. 2000;11(1):59-67.
30. Amarante ECJ, Kasamatsu TS, Kunii IS, Vieira JG. Avaliação da excreção urinária de piridinolina e deoxipiridinolina em pacientes com hipertiroidismo e sua correlação com níveis de hormônios tiroidianos e densidade mineral óssea. Arq Bras Endocrinol Metab. 1996;40:258-63.
31. Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. 2007;22(8):1155-64.
32. Lems WF, Van Veen GJ, Gerrits MI, Jacobs JW, Houben HH, Van Rijn HJ, et al. Effect of low dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. Br J Rheumat. 1998;37(1):27-33.
33. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of lowdose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464-70.
34. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305-10.
35. Smellie WS. What is a significant difference between sequential laboratory results? J Clin Pathol. 2008;6(4)1:419-25.
36. Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63(1):19-26.
37. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19(8):1250-8.
38. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18(6):1051-6.
39. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone. 2006;39(6):1268-75.
40. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin. 2006;22(1):61-6.
41. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol Diagn Ther. 2008;12(3):157-70.
42. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337-49.
43. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15(8):1526-36.
44. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20(10):1813-9.
45. Robbins JA, Schott AM, Garnero P, Delmas PD, Hans D, Meunier PJ. Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int. 2005;16(12):149-54.
46. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108-12.
47. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int. 1999;65(5):359-64.
48. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006;21(12):291-99.
49. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31.
50. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653-61.
51. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, et al Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45(6):1053-8.
52. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459-68.
53. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137(11):875-83.
54. Ivaska KK, Gerdhem P, Väänänen HK, Akesson K, Obrant KJ. Bone turnover markers and prediction of fracture: a prospective followup study of 1040 elderly women for a mean of nine years. J Bone Miner Res. Epub 2009 Dec 6.